SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) financial statements, including revenue, expenses, profit, and loss

The total revenue of 0QN1 for the last semiannual is 99.44 M CHF, and it's 2424.42% higher compared to the previous semiannual. The net income of H2 23 is 78.12 M CHF.